Login / Signup

Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports.

Mandeep Kumar AroraHarikesh DubeyMandeep Kumar Arora
Published in: Current drug safety (2024)
ICIs were significantly associated with neurologic risks, which cannot be generalized. A considerable increase in ICSR reporting frequency was observed with atezolizumab, cemiplimab, and nivolumab, while avelumab, pembrolizumab, durvalumab, and cemiplimab were linked with four potential signals. These findings suggest the consideration of a revision of the neurologic safety profile of ICIs. Furthermore, the necessity for additional ad-hoc research is emphasized.
Keyphrases
  • adverse drug
  • electronic health record
  • emergency department
  • human health
  • total knee arthroplasty
  • drug induced
  • risk assessment
  • climate change